“Bringing to life the science around innovative new drugs, gene & cell therapies” 

Novel Targets is a science podcast that brings to life the science and people involved in the development of innovative new drugs, gene and cell therapies.

Over 4 seasons from 2015 to 2018 we captured a landmark period in cancer drug development and cancer immunotherapy research culminating in the award of the 2018 Novel Prize in Physiology or Medicine that we covered in Episode 26.

Novel Targets aims to inform, educate and create awareness; it occasionally entertains.

Episodes look at emerging new targets and approaches that could make a difference to the lives of patients. The podcast discusses data from clinical trials and engages experts. It reaches a broad global audience of “influencers” and stakeholders in the cancer research community.

Novel Targets is currently on hiatus due to the end of our long-standing sponsorship.

In the event new sponsorship is obtained, we may be back for Season 5 and a new voyage of discovery, but currently no new episodes are planned. Follow us on Twitter @TargetsPodcast if you want to keep in touch.

If you enjoy the podcast, then do consider supporting independent science journalism and becoming a subscriber to Biotech Strategy Blog. It’s where you’ll find us writing about cancer new product development.

Sally Church, PhD

Sally is the executive producer of Novel Targets and ensures the scientific accuracy of the show’s output.

A digital media entrepreneur, she’s a member of the National Association of Science Writers (NASW) and Association of Health Care Journalists (AHCJ).

Over the last 10+ years she’s written close to two thousand posts on the science driving cancer drug development, firstly on Pharma Strategy Blog and then on her independent, subscription funded publication Biotech Strategy Blog.

Follow Sally on Twitter: @MaverickNY


Genentech Corporate LogoGenentech (@Genentech) sponsored Novel Targets for 4 seasons ending with Episode 26, “Coming Full Circle.”

Each episode Genentech supported usually featured a short vignette or mini-interview with one of their scientists that highlighted their passion in “helping people combat the world’s hardest-to-treat diseases.

The Loncar Cancer Immunotherapy Index sponsored Episode 14: Cell Therapy Pioneers.

It reached No 21 in the US iTunes/Apple Podcasts chart for Medicine related podcasts.

We’re grateful for all the sponsor support we’ve obtained without which the podcast would not have happened!

Editorial Policy

If we do mention any products or people from any sponsor (outside of the sponsorship mention) in any episode, then it’s because we thought they merited commentary or inclusion.

The podcast is editorially independent – sponsors have no control over content, who we interview, what topics we talk about or the questions we ask!